New immunotherapy options for liver cancer

December 2018

Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center, is currently conducting more than 120 research studies, including clinical trials of targeted therapies and novel immunotherapy approaches.

Checkpoint inhibitors are showing promise as a potential new line of treatment for people with liver cancer. Providence Cancer Institute currently has six studies open to liver cancer patients, including two new studies investigating checkpoint inhibitors:

A study of nivolumab for patients at high risk of recurrence after curative surgery.
A study of durvalumab plus tremelimumab for patients with unresectable liver cancer.

Read More About These Studies

All current open studies:

Brain Cancer
Breast Cancer
Gastrointestinal Cancers
Genitourinary Cancers
Gynecologic Cancers

Head and Neck Cancers
Hematologic Cancers
Lung Cancer
Melanoma
Phase 1 Trials

Find additional studies for many types of cancer in Multiple Tumor Types .

New studies are posted frequently - please check our website for a complete list of our current studies. For more information, call 503-215-2614.

Refer A Patient

Email Our Team

See All Open Studies

Earle A. Chiles Research Institute